Barron's senior managing editor Lauren R. Rublin and healthcare industry reporter Josh Nathan-Kazis discuss the outlook for healthcare stocks, and the latest news on Covid-19 treatments and vaccines.
Jul 20
The Bullish Trend Is Your Friend: Talking Stocks With Sam Stovall
A decent first half of the year for the stock market implies more gains in the second half, says Sam Stovall, chief investment strategist at CFRA Research. Stovall discusses his economic and investment outlook, and the prospects for the S&P's 11 industry sectors, with Barron's Se ... Show More
42m 24s
Jul 13
Quality Stocks on Sale: An Update from the Barron's Roundtable's Christopher Rossbach
As investors have piled into the AI trade, shares of many high-performing companies have been left on the sidelines, their shares in the bargain bin. That's where most members of the Barron's Roundtable tend to shop, including Christopher Rossbach, a managing partner and chief in ... Show More
42m 10s
Mar 2020
Live from the Compound (from Long Island)
Michael Batnick and Downtown Josh Brown discuss all of the recent market volatility from the COVID-19 situation, including some takes on stock buybacks, what 13Fs might look like, the 10 stocks that have raised their dividends for 50 years straight, the overall damage so far and ... Show More
21m 48s
Nov 2020
COVID-19 Vaccine Optimism, Business Leaders' Message To President Trump, And Retail Stocks' Big November Rally
<p>Kicking off a holiday-shortened week for the markets, Jim Cramer and David Faber highlighted the latest vaccine news to lift stocks: AstraZeneca announced that its COVID-19 vaccine being developed in conjunction with Oxford University was up to 90 percent effective with no ser ... Show More
42m 24s
Apr 2020
Gilead Virus Treatment Is Promising But No Silver Bullet Yet
Sam Fazeli, Director of Research: EMEA for Bloomberg Intelligence, on Gilead's positive trial for a potential coronavirus treatment. Lisa Shalett, Chief Investment Officer: Wealth Management for Morgan Stanley, discusses why she wants clients to avoid S&P indices and to actively ... Show More
30m 3s